3 Results for "

DART

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "DART" in MCE Product Catalog:

Referencia número: HY-P99623
No. CAS: 1664355-28-5
Synonyms: MGD006; S80880

Target:  

CD3

Áreas de investigación:  

Cancer

Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .
loading...
    loading...
Referencia número: HY-P99714
No. CAS: 2416595-46-3
Synonyms: MGD019

Target:  

PD-1/PD-L1 CTLA-4

Áreas de investigación:  

Cancer

Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .
loading...
    loading...
Referencia número: HY-P99573
No. CAS: 2245725-04-4
Synonyms: MGD013

Target:  

LAG-3

Áreas de investigación:  

Inflammation/Immunology Cancer

Tebotelimab (MGD013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC50s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity .
loading...
    loading...